8-K
filed March 12, 2026, 7:59 PM ET
ticker IGC
CIK 0001326205
debt
confidence high
sentiment neutral
materiality 0.55
IGC Pharma, Inc. (IGC): debt financing — IGC Pharma issues $353K convertible note to Vanquish Funding; also obtains $219K loan
IGC Pharma, Inc.
- Principal $353,050 includes $46,050 original issue discount; net proceeds $307,000 for working capital.
- Upon default, holder can convert at 75% of lowest 10-day trading price, subject to 4.99% ownership cap.
- Additional tranche up to $2,015,000 over 12 months available subject to further agreement.
- Separate loan from One Deck Capital of ~$219,000 with scheduled periodic payments for general corporate purposes.
- Conversion capped at 19.99% of outstanding shares without shareholder approval per NYSE American rules.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
IGC Pharma, Inc. incurred loan of approximately $219,000 with One Deck Capital, Inc..
- Instrument
- loan
- Principal
- approximately $219,000
- Counterparty
- One Deck Capital, Inc.
- Event
- incurrence
Exact text from the filing
The Company entered into a loan agreement with One Deck Capital, Inc. (“One Deck”), pursuant to which the Company received approximately $219,000 in financing (the “One Deck Loan”).
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
IGC Pharma, Inc. incurred loan of $353,050 with Vanquish Funding Group Inc. maturing February 28, 2027.
- Instrument
- loan
- Principal
- $353,050
- Counterparty
- Vanquish Funding Group Inc.
- Maturity
- February 28, 2027
- Event
- incurrence
Exact text from the filing
On March 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
IGC Pharma, Inc. entered into a credit facility with One Deck Capital, Inc. valued at approximately $219,000.
- Action
- entry
- Agreement
- credit facility
- Counterparty
- One Deck Capital, Inc.
- Value
- approximately $219,000
Exact text from the filing
The Company entered into a loan agreement with One Deck Capital, Inc. (“One Deck”), pursuant to which the Company received approximately $219,000 in financing (the “One Deck Loan”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
IGC Pharma, Inc. entered into Securities Purchase Agreement with Vanquish Funding Group Inc. (effective 2026-03-05).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Vanquish Funding Group Inc.
- Effective
- 2026-03-05
Exact text from the filing
On March 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corporation (“VFG” or the “Holder”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
IGC Pharma, Inc. entered into Promissory Note with Vanquish Funding Group Inc. valued at $353,050 (effective 2026-03-05).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Vanquish Funding Group Inc.
- Value
- $353,050
- Effective
- 2026-03-05
Exact text from the filing
Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to VFG with a total principal amount of $353,050
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.